154142-59-3

Basic information

• Product Name: methyl 3-methoxybenzenecarbimidothioate hydroiodide
• Synonyms: methyl 3-methoxybenzenecarbimidothioate hydroiodide
• CAS NO: 154142-59-3
• Molecular Weight: 309.171
• Mol File: 154142-59-3.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: methyl 3-methoxybenzenecarbimidothioate hydroiodide(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3-methoxybenzenecarbimidothioate hydroiodide(154142-59-3)
• EPA Substance Registry System: methyl 3-methoxybenzenecarbimidothioate hydroiodide(154142-59-3)

Safety Data

• Hazardous Substances Data: 154142-59-3(Hazardous Substances Data)

Upstream product

• 64559-06-4 3-methoxythiobenzamide 
• 74-88-4 methyl iodide 

Downstream Products

• 1000276-99-2 2-{[(4-{[(4-{[imino(4-methoxy-2-pyridinyl)methyl]amino}-1-methyl-1H-pyrrol-2-yl)carbonyl]amino}-1-methyl-1H-pyrrol-2-yl)carbonyl]amino}-5-isopropyl-N-[2-(4-morpholinyl)ethyl]-1,3-thiazole-4-carboxamide 
• 1000277-03-1 C₃₃H₃₅N₉O₄ 
• 1000276-96-9 N-[3-(dimethylamino)propyl]-2-{[(4-{[(4-{[imino(3-methoxyphenyl)methyl]amino}-1-methyl-1H-pyrrol-2-yl)carbonyl]amino}-1-methyl-1H-pyrrol-2-yl)carbonyl]amino}-5-isopentyl-1,3-thiazole-4-carboxamide 
• 1000277-01-9 4-{[(4-{[imino-(3-methoxyphenyl)methyl]amino}-1-methyl-1H-pyrrol-2-yl)carbonyl]amino}-1-methyl-N-[1-methyl-5-({[3-(4-morpholinyl)propyl]amino}carbonyl)-1H-pyrrol-3-yl]-1H-pyrrole-2-carboxamide 
• 1000276-89-0 N-[3-(dimethylamino)propyl]-4-{[(4-{[(4-{[imino(3-methoxyphenyl)methyl]amino}-1-methyl-1H-pyrrol-2-yl)carbonyl]amino}-1-methyl-1H-pyrrol-2-yl)carbonyl]amino}-1-methyl-1H-pyrrole-2-carboxamide 
• 1000276-97-0 C₃₂H₃₉N₉O₅ 
• 1000276-86-7 N-[5-({[5-({[3-(dimethylamino)propyl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]amino}carbonyl)-1-isopropyl-1H-pyrrol-3-yl]-4-{[imino-(3-methoxyphenyl)methyl]amino}-1-methyl-1H-pyrrole-2-carboxamide 
• 1000276-87-8 C₃₂H₄₁N₉O₄S 

Relevant articles and documents

An evaluation of Minor Groove Binders as anti-lung cancer therapeutics

A series of 47 structurally diverse MGBs, derived from the natural product distamycin, was evaluated for anti-lung cancer activity by screening against the melanoma cancer cell line B16-F10. Five compounds have been found to possess significant activity, more so than a standard therapy, Gemcitabine. Moreover, one compound has been found to have an activity around 70-fold that of Gemcitabine and has a favourable selectivity index of greater than 125. Furthermore, initial studies have revealed this compound to be metabolically stable and thus it represents a lead for further optimisation towards a novel treatment for lung cancer.